Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04479800 · ClinicalTrials.gov registry record · Phase 1
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT04479800 is a Phase 1 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT04479800, a Phase 1 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a Phase 1, single-dose, open-label, randomized, three-period, three-way crossover study in which healthy adult participants will receive three separate single-dose administrations of ASTX660 capsules under three different conditions.
Interventions
- DRUG ASTX660
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2020-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04479800
The ClinicalTrials.gov registry entry for NCT04479800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASTX660 is the first listed.
NCT04479800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04479800 about?
NCT04479800 is a clinical study titled "Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers". This is a Phase 1, single-dose, open-label, randomized, three-period, three-way crossover study in which healthy adult participants will receive three separate single-dose administrations of ASTX660 capsules under three different conditions.
What is the current status of trial NCT04479800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2020-07-20. Estimated completion is 2020-08-25.
What interventions are being tested in trial NCT04479800?
The interventions under investigation include: ASTX660 (DRUG).
Who is sponsoring clinical trial NCT04479800?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.